skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

33 Total results for product and free and sample content found

Datamonitor Healthcare

Chronic Lymphocytic Leukemia

By Dominique Fontanilla 15 Feb 2017

While Rituxan-based therapies remain dominant in the first-line treatment setting for early- and late-stage chronic lymphocytic leukemia (CLL), the majority of patients with relapsed or refractory disease receive Imbruvica. 

Topic Research wire

Datamonitor Healthcare

Merck & Co looks to strengthen Keytruda’s first-line lead in NSCLC with chemotherapy combination

By Dustin Phan 12 Jan 2017

Accelerated approval of Keytruda in combination with chemotherapy for NSCLC could serve to strengthen the drug’s first-line lead by expanding the eligible patient population to include all PD-L1 expression levels.

Topic Research wire

Datamonitor Healthcare

Praluent US sales block gives advantage to Amgen's Repatha in dyslipidemia

By Kevin Shannon 06 Jan 2017

On 5 January, Amgen secured a court ruling blocking Praluent (alirocumab; Sanofi/Regeneron) from being sold in the US. This ruling clears the way for Amgen’s Repatha (evolocumab) to potentially become the sole proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor in the US market.

Topic Research wire

Datamonitor Healthcare

Despite the failure of solanezumab’s EXPEDITION 3 trial, hope for the amyloid hypothesis lingers on

By Maha Elsayed 12 Dec 2016

At the 2016 Clinical Trials on Alzheimer’s Disease (CTAD) meeting, Eli Lilly provided a more detailed explanation for the failure of solanezumab in its pivotal EXPEDITION 3 study in mild Alzheimer’s disease.

Topic Research wire Alzheimers

Datamonitor Healthcare

AHA 2016: Type 2 diabetes treatment is shifting towards therapies with cardiovascular benefits

By Kevin Shannon 22 Nov 2016

Controversies to Consensus session at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans discussed how recent results from cardiovascular outcomes trials should affect current treatment and regulatory practices.

Topic Research wire

Datamonitor Healthcare

AHA 2016: EFFECT-HF supports use of iron deficiency as an independent therapeutic target in heart failure

By Kevin Shannon 22 Nov 2016

Topline results from the Phase III EFFECT-HF study of Injectafer (ferric carboxymaltose; Genesis Pharma/The Galenica Group/Zeria) and its impact on exercise capacity in chronic heart failure patients with iron deficiency were presented at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans.

Topic Research wire

Datamonitor Healthcare

AHA 2016: Interim Data from ORION-1 Trial Encourage Further Development of Inclisiran

By Jack Allen 22 Nov 2016

Inclisiran offers patients a more convenient dosing schedule that may allow it to compete with marketed PCSK9 inhibitors when approved.

Topic Research wire

Datamonitor Healthcare

AHA 2016: PIONEER-AF trial results will have minimal effect on Xarelto uptake

By Jack Allen 18 Nov 2016

Reduced doses of Xarelto were shown to lower the rate of bleeding in the PIONEER-AF trial. However, questions still remain as to how efficacious the smaller doses of Xarelto tested in the trial are at protecting against stroke.

Topic Research wire

Datamonitor Healthcare

AHA 2016: Repatha causes atherosclerotic plaque regression, even at very low LDL-C levels

By Jack Allen 17 Nov 2016

The Phase III GLAGOV trial showed Repatha (evolocumab; Amgen/Astellas) treatment to reduce atherosclerotic plaque burden in an apparently dose-dependent manner, even at very small low-density lipoprotein-cholesterol (LDL-C) levels.

Topic Research wire

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:
Pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: